Combination of bevacizumab (A) and pegylated-liposomal doxorubicin (PLD) (PLD-A) in sarcoma (SAR).

被引：0
|
作者：
Haddad, P. A.
Skubitz, K. M.
机构：
[1] LSU Hlth Sci Ctr, Shreveport, LA USA
[2] Univ Minnesota, Minneapolis, MN 55455 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9556
引用
收藏
页码：533S / 533S
页数：1
相关论文
共 50 条
  • [31] Pegylated liposomal doxorubicin (PLD) as an alternative treatment of cutaneous T-cell lymphoma
    Quereux, G.
    Khammari, A.
    Nguyen, J. M.
    Benmiloud, M.
    Dreno, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin (PLD): Use of left ventricular ejection fraction (EF).
    Skubitz, Keith M.
    Blaes, Anne Hudson
    Konety, Suma
    Francis, Gary S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).
    Muggia, F.
    Safra, T.
    Borgato, L.
    Gandhi, A.
    Mancinc, G.
    Gabizon, A.
    Liebes, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Chemotherapy with Pegylated Liposomal Doxorubicin (PLD) in Combination with PUVA and Interferon-Alpha in Stage IIB Mycosis Fungoides (MF)
    Mebes, K.
    von den Driesch, P.
    AKTUELLE DERMATOLOGIE, 2006, 32 (07) : 322 - 325
  • [35] Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer
    Monk, B. J.
    Herzog, T. J.
    Kaye, S. B.
    Krasner, C. N.
    Vermorken, J. B.
    Muggia, F.
    Pujade-Lourraine, E.
    Zintl, P.
    Parekh, T. V.
    Poveda, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma
    Skubitz, KM
    Haddad, PA
    CANCER, 2005, 104 (02) : 361 - 366
  • [37] TRABECTEDIN AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VERSUS CARBOPLATIN AND PLD IN PARTIALLY PLATINUM-SENSITIVE OVARIAN CANCER PATIENTS: INOVATYON STUDY
    Colombo, N.
    Biagioli, E.
    Copreni, E.
    Floriani, I.
    Fossati, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 457 - 457
  • [38] Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma
    Hjortsberg, C
    Persson, U
    Lidbrink, E
    Bennett, C
    ACTA ONCOLOGICA, 1999, 38 (08) : 1063 - 1067
  • [39] Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: A systematic review
    Di Trolio, R.
    Di Lorenzo, G.
    Delfinoi, M.
    De Placido, S.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2006, 19 (02) : 253 - 263
  • [40] Combination of Pegylated Liposomal Doxorubicin (PLD) and ifosfamide (IFO) in patients with advanced soft tissue sarcoma (STS). A phase II study of the Hellenic Cooperative Oncology Group
    Bafaloukos, Dimitrios
    Kosmidis, Paris
    Briasoulis, Evangelos
    Gogas, Helen
    Aravantinos, Gerasimos
    Papadimitriou, Christos
    Economopoulos, Theofanis
    Papakostas, Pavlos
    Fountzilas, George
    ANNALS OF ONCOLOGY, 2004, 15 : 198 - 198
12345